###### Key messages

What is the key question?
=========================

-   Can a supervised pulmonary tele-rehabilitation programme, including structured exercise and education, deliver higher programme-adherence and thereby superior benefits to a conventional hospital-based pulmonary rehabilitation (PR) programme for patients with severe COPD?

What is the bottom line?
========================

-   This pulmonary tele-rehabilitation model demonstrated short-term and medium-term improvements in functional capacity and disease-related symptoms that were not superior to conventional hospital-based PR for patients with severely progressed COPD.

Why read on?
============

-   Despite the benefits, PR programmes are challenged by low participant uptake, insufficient attendance and high drop-out rates; supervised pulmonary tele-rehabilitation may be a useful second-line option to improve access for patients with severe COPD who cannot participate in or comply with a conventional hospital-based PR programme.

Introduction {#s1}
============

Pulmonary rehabilitation (PR) is recognised as an important, standard treatment for people with chronic obstructive pulmonary disease (COPD). PR is well documented to reduce symptoms and increase walking capacity and quality of life (QoL), but its effect on physical activity level (PAL) is limited.[@R1] Despite the benefits, PR programmes are challenged by low participant uptake, insufficient attendance and high drop-out rates.[@R6] Barriers have previously been reported, including transportation issues, symptom severity, acute exacerbations, lack of energy and disruption of daily routines.[@R6] Recently, the American Thoracic Society (ATS)/European Respiratory Society (ERS) recommended investigating alternative approaches to PR, such as tele-rehabilitation, in an attempt to increase uptake and make PR available to more patients.[@R12] To date, two randomised controlled trials (RCTs) have explored the effect of unsupervised web-based or video-demonstrated individual exercise and education compared with conventional group-based PR in patients with stable moderate-to-severe COPD.[@R13] The studies did not find differences between interventions for outcomes of walking capacity and respiratory symptoms.[@R13] One study including patients with COPD and comorbid heart failure (NYHA II-IV) compared home-monitored exercise and weekly individual telephone supervision with usual care (no intervention). The intervention provided clinically relevant differences in walking capacity, respiratory symptoms and QoL compared with usual care. Furthermore per-protocol analyses showed that the gains were maintained at the 2-month follow-up.[@R15] Lastly, in patients with moderate COPD, one small RCT study (n=37) compared usual care (no intervention) with a supervised pulmonary tele-rehabilitation (PTR) programme in groups of two to four patients.[@R16] This study showed significant and clinically relevant between-group difference on endurance shuttle walk, anxiety and depression symptoms and self-efficacy in favour of supervised PTR.[@R16] All four studies are limited in their conclusions as none declared a priori-design (superior, equivalence, non-inferior) in the trial registry protocol, and just two studies stated a hypothesis.[@R14] Although results from the recent PTR studies are promising, effects from supervised PTR in groups compared with conventional outpatient supervised PR in groups remain to be investigated. Consequently, evidence is needed to ascertain any possible effect of a fully supervised real-time PTR programme on relevant outcomes. To our knowledge, our study is the first RCT investigating the short-term and medium-term effect of a supervised PTR programme compared with a supervised conventional PR programme on walking capacity, symptoms, QoL and PAL in patients with COPD, FEV~1~ \<50% and a high symptom burden eligible for routine hospital-based outpatient PR. We hypothesised that the supervised PTR programme would be superior to a supervised conventional PR regarding change in 6 min walk distance (6MWD) because of an expected higher adherence rate, leading to a greater response.[@R17] This paper reports on the clinical outcomes. A full economic analysis will be published separately.

Methods {#s2}
=======

Trial design and participants {#s2-1}
-----------------------------

We conducted a randomised clinical, assessor-blinded and statistician-blinded, superiority, multicentre trial with two parallel groups to investigate the effect of supervised PTR compared with conventional PR on walking capacity in patients eligible for outpatient hospital-based PR. Patients were recruited from the respiratory departments of eight different university hospitals in Greater Copenhagen during March 2016 to October 2017. Inclusion and exclusion criteria corresponded to the criteria for outpatient hospital-based routine PR in the Capital Region of Copenhagen, Denmark, and pertained to adults with a clinical diagnosis of COPD defined as FEV1/FVC \<0.70, FEV1 \<50%, Medical Research Council ≥2 and no participation in PR within 6 months of the start of intervention.[@R17] All patients provided written and verbal informed consent.

Randomisation and blinding {#s2-2}
--------------------------

After baseline assessments, patients were randomly allocated 1:1 to receive PTR or conventional hospital-based PR. The allocation followed a computer-generated randomisation list made by a biostatistician for each recruiting hospital; treatment was denoted as A and B to ensure blinding of the biostatistician. A senior manager from an independent research department was responsible for the randomisation list and provided the draw to ensure concealment. All assessors were blinded to group allocation, hypotheses and intervention details. Patients were not possible to blind for allocation. In the case of failure to keep the assessor blinded, a second assessor was available to conduct the blinded assessment on another day. The biostatistician had the main responsibility for the data analyses.

Intervention {#s2-3}
------------

### Pulmonary tele-rehabilitation {#s2-3-1}

The details and appropriate dosage set-up from both intervention programs are available in the [online supplementary material](#SP1){ref-type="supplementary-material"} and in our previously published protocol article.[@R17] In brief, the PTR programme was designed by the study group and aligned with exercise intensities and education themes from conventional PR. It was a group-based, supervised and standardised programme performed by the patients in their homes three times weekly for 10 weeks via a videoconference software system installed on a single touch screen. The exercise sessions lasted 35 min (weekly exercise volume 105 min) with incorporated warm-up and high repetitive time-based muscle endurance training followed by 5 min' rest before beginning a patient education session of 20 min (weekly education volume 60 min).
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### Conventional pulmonary rehabilitation {#s2-3-2}

The conventional outpatient hospital-based PR programme was group-based, supervised and standardised and was performed twice a week for 10 weeks (in one hospital, for 12 weeks). The programme followed the Danish Health Authority's National Clinical Guideline and the Regional Guidelines.[@R17] The exercise sessions lasted 60 min and incorporated warm-up, endurance and resistance training and a cool-down period (weekly exercise volume 120 min). The patient education sessions lasted 60 to 90 min and took place once a week after the exercise session (detailed [online supplementary](#SP1){ref-type="supplementary-material"} available).

Outcomes {#s2-4}
--------

Full details on outcome, assessment procedures and quality control are available in the [online supplementary material](#SP1){ref-type="supplementary-material"}. Briefly, the primary outcome was change in the 6MWD on completion of the programme. Secondary outcomes were COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), EuroQol 5-Dimension Questionnaire (EQ-5D), the 30 s sit-to-stand test (30sec-STS), Clinical COPD Questionnaire (CCQ) and Physical Activity Level (PAL). The PAL was measured with activePAL triaxial accelerometer (PAL Technologies Ltd, Glasgow, UK) worn 24 hours for 5 days. PAL was measured on 73 patients residing within a radius of 25 km of Bispebjerg University Hospital. All assessment procedures were performed at baseline, end of intervention and at 22 weeks' follow-up from baseline. The procedures were reproducible and have been published.[@R21] Descriptive variables included body mass index, smoking status, medication and Charlson Comorbidity Index, spirometry and anthropometric measures, which followed the standardised protocols from the Danish Society of Respiratory Medicine.[@R22] Adverse events, hospitalisations and deaths were recorded throughout the trial by the National Health Data Authorities.

Statistical analysis {#s2-5}
--------------------

For the 6MWD, a change of 26 m is considered a minimal clinically important difference (MCID) in patients with COPD and FEV1 \<50%.[@R23] Based on a two-sample independent t-test with an MCID of 26 m, a SD of 44.6 m,[@R24] a power of 80%, a significance level of 0.05 and an anticipated drop-out rate of 30%, 134 patients were recruited. Using this sample size, expected SD and existing MCID, power estimations for the secondary outcomes revealed 80% power to detect MCID in all secondary outcomes except CCQ and PAL.[@R17] Descriptive data for the PTR and conventional PR are presented as mean and SD for continuous variables and frequency for categorical variables. Differences between the intervention groups in change of primary and secondary outcomes (end of intervention - baseline and 22 weeks' follow-up - baseline) were analysed by mixed effect models. The models included adjustment for treatment group, age, sex, body mass index, FEV~1~, Charlson Comorbidity Index, smoking status and a random effect for hospital allocation. To account for possible regression to the mean effect, the baseline measure for the outcome was also included as a fixed effect variable in the models. Normal distribution of the model residuals was evaluated by Q-Q plots. All data are considered missing at random, using this with the likelihood-estimation in the mixed effect model, the ignorability assumption for the likelihood estimator is used to account for missing data in the model estimates[@R26] (number of data sets is stated in [tables 1 and 2](#T1 T2){ref-type="table"} and [online supplementary tables S2 and S3](#SP1){ref-type="supplementary-material"}). Group differences on number of patients remaining in their programmes for the full intervention period, adherence, hospitalisation and death were analysed with χ^2^ test. Adherence/attendance was defined as a patient participating in an entire scheduled exercise and education session. Analysis of age and sex differences between patients with and without outcome measures was done by χ^2^ and Wilcoxon rank-sum test. Per-protocol analysis included patients attending ≥70% of the planned sessions. Statistical analyses were carried out using R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). P values of less than 0.05 were considered statistically significant.

###### 

Baseline characteristics

  Variables                                         All (n=134)     PTR (n=67)      PR (n=67)
  ------------------------------------------------- --------------- --------------- --------------
  Female sex, n (%)                                 74 (55)         35 (52)         39 (58)
  Age, year                                         68.3 (9.0)      68.4 (8.7)      68.2 (9.4)
  Body mass index, kg/m^2^                          25.7 (5.8)      25.5 (5.0)      25.9 (6.4)
  FEV1, % predicted                                 33.1 (9.4)      32.6 (10.3)     33.7 (8.4)
  FEV1/FVC, %                                       43.3 (11.2)     43.9 (11.3)     42.7 (11.1)
  GOLD I/II/III/IV, %                               0/0/61/39       0/0/55/45       0/0/67/33
  A/B/C/D, %                                        2/34/4/60       5/34/3/58       0/33/4/63
  LTOT, n (%)                                       20 (15)         11 (16)         9 (13)
  SpO2 at rest, %                                   94.6 (2.8)      94.6 (2.4)      94.8 (3.1)
  MRC 1/2/3/4/5, n                                  0/2/65/50/17    0/2/30/27/8     0/0/35/23/9
  Smoking status, n (%)                                                             
   Never                                            3 (2)           2 (3)           1 (1)
   Former                                           99 (75)         51 (79)         48 (72)
   Current                                          30 (23)         12 (18)         18 (27)
  Pack-year history, mean (SD)                      43.5 (20.2)     42.4 (23.1)     44.5 (17.3)
  BODE index points, median (IQR)                   5.0 (4--6)      5.0 (4--7)      5.0 (4--6)
  Charlson Comorbidity Index 1/2/≥3, (%)            40/37/23        45/40/15        34/33/33
  Exacerbations, previous 12 month, (median, IQR)   2 (0--3)        2 (0--4)        2 (1--3)
  Current medication, n (%)                                                         
   SABA                                             112 (84)        56 (84)         56 (84)
   SABA + SAMA                                      11 (8)          6 (9)           5 (7)
   LABA                                             2 (1)           1 (1)           1 (1)
   LAMA                                             3 (2)           2 (3)           1 (1)
   LABA + LAMA                                      24 (18)         12 (18)         12 (18)
   LABA + ICS                                       8 (6)           5 (7)           3 (5)
   LABA + LAMA + ICS                                93 (69)         45 (67)         48 (71)
   Oral steroids                                    2 (1)           2 (3)           0 (0)
  Walking aid, walker/other, n (%)                  27/18 (34)      14/9 (34)       13/9 (33)
  Highest 6MWD, metre                               327.3 (102.8)   322.3 (108.3)   332.3 (97.5)
  Highest 30sec-STS, repetitions                    9.8 (4.3)       9.9 (4.7)       9.6 (3.8)
  Physical activity level\*                                                         
   Daily step count, steps                          3091 (2161)     2779 (1966)     3422 (2335)
   Time sedentary, min                              1205 (133)      1244 (121)      1164 (134)
   Time active, min                                 235 (133)       196 (121)       276 (134)
  CAT, score                                        20.1 (7.0)      19.8 (7.3)      20.4 (6.6)
  HADS, score                                                                       
   HADS-anxiety                                     6.3 (3.5)       6.8 (3.8)       5.9 (3.1)
   HADS-depression                                  4.3 (3.0)       4.5 (2.)        4.1 (3.1)
  EQ-5D, VAS score                                  52.7 (19.2)     51.5 (19.4)     53.9 (19.1)
  EQ-5D, index score                                0.68 (0.16)     0.66 (0.20)     0.70 (0.12)
  CCQ, score                                                                        
   Symptoms                                         2.9 (1.2)       2.8 (1.2)       3.0 (1.2)
   Functional                                       2.9 (1.2)       2.8 (1.1)       3.0 (1.3)
   Mental                                           2.8 (1.4)       2.8 (1.5)       2.9 (1.4)
   Total                                            2.8 (0.9)       2.7 (0.9)       2.9 (1.0)

Data are presented as mean (SD) except where otherwise indicated.

\*ActivePAL triaxial accelerometer worn by in total 73 patients (PTR/PR: 37/36). Any statistically significant difference between PTR and PR denoted \*p\<0.05.

A/B/C/D, risk stratification, airflow obstruction, dyspnea and exercise capacity; BODE index, body mass index; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; EQ-5D, Euro-Qol 5-dimension; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Score; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTOT, long-term oxygen therapy; MRC, Medical Research Council; 6MWD, 6 min walk distance; PR, pulmonary rehabilitation; PTR, pulmonary tele-rehabilitation; SABA, short-action β2-agonist; SAMA, short-acting muscarinic antagonist; 30-sec STS, 30 s sit-to-stand test; SpO2, arterial oxygen saturation as measured by pulse oximetry; VAS, Visual Analogue Scale.

###### 

Between-group differences in primary and secondary outcomes in PTR and PR groups. Intention-to-treat principle

                        Between-group differences from baseline (95% CI)                                                  
  --------------------- -------------------------------------------------- ----------------------- ---------------------- -----------------------
  Primary outcome                                                                                                         
   6MWD, min            6.3 (−9.8 to 22.5)                                 −11.0 (−34.4 to 12.4)   8.3 (−7.7 to 24.3)     −3.9 (−27.9 to 19.9)
  Secondary outcomes                                                                                                      
   30sec-STS, reps      0.5 (−0.6 to 1.5)                                  0.4 (−0.7 to 1.4)       0.5 (−0.6 to 1.5)      0.5 (−0.6 to 1.6)
   CAT, points          1.4 (−0.1 to 3.0)                                  −0.5 (−2.6 to 1.5)      1.6 (0.1 to 3.3)\*     −0.2 (−2.1 to 1.8)
  HADS                                                                                                                    
   Anxiety, points      1.1 (0.1 to 2.1)\*                                 0.2 (−0.9 to 1.4)       1.2 (0.2 to 2.3)\*     0.4 (−0.8 to 1.6)
   Depression, points   0.7 (−0.1 to 1.5)                                  −0.2 (−1.3 to 1.0)      0.9 (0.1 to 1.7)\*     −0.2 (−1.3 to 1.0)
   EQ-5D-VAS, points    −0.2 (−6.4 to 5.9)                                 0.8 (−5.8 to 7.5)       −0.2 (−6.2 to 5.9)     1.6 (−5.1 to 8.3)
  CCQ                                                                                                                     
   Function, points     0.1 (−0.2 to 0.5)                                  0.1 (−0.2 to 0.5)       0.1 (−0.2 to 0.5)      0.2 (−0.2 to 0.5)
   Mental, points       0.1 (−0.3 to 0.6)                                  −0.1 (−0.4 to 0.3)      0.3 (−0.2 to 0.7)      0.1 (−0.3 to 0.5)
   Symptoms, points     0.2 (−0.1 to 0.5)                                  0.1 (−0.3 to 0.5)       0.2 (−0.1 to 0.5)      0.1 (−0.2 to 0.5)
   Total, points        0.2 (−0.1 to 0.4)                                  0.1 (−0.2 to 0.3)       0.2 (−0.1 to 0.5)      0.1 (−0.1 to 0.4)
  PAL                                                                                                                     
   Steps per day        −283 (−845 to 278)                                 −302 (−1035 to 419)     −436 (−1010 to 138)    −103 (−886 to 597)
   Sedentary, min       9.4 (−35.2 to 51.3)                                8.6 (−53.8 to 36.6)     7.7 (−49.0 to 52.2)    14.6 (−32.5 to 58.5)
   Active, min          −9.4 (−51.3 to 35.4)                               −8.6 (−36.6 to 53.8)    −7.7 (−52.2 to 49.0)   −14.6 (−58.5 to 32.5)

Data are mean difference (95% CI).

\*P value for group mean change differences \<0.05.

†Complete observations (n) used for the likelihood estimate from end of rehabilitation to baseline (total): 6MWD: (115); 30sec-STS: (115); CAT: (119); HADS: (110); EQ-5d-VAS: (119); CCQ: (119); PAL: (59).

‡Complete observations (n) used for the likelihood estimate from 22 weeks' follow-up from baseline to baseline (total): 6MWD: (95); 30sec-STS: (95); CAT: (106); HADS: (100); EQ-5d-VAS: (104); CCQ: (106); PAL: (55).

CAT, COPD Assessment Test; CCQ, COPD Clinical Questionnaire; EQ-5D, EuroQol 5-Dimension Questionnaire; HADS, Hospital Anxiety and Depression Scale; 6MWD, 6 min walk distance; PAL, physical activity level; PR, pulmonary rehabilitation; PTR, pulmonary tele-rehabilitation; 30sec-STS, 30 s sit-to-stand test; VAS, Visual Analogue Scale.

###### 

Within-group changes in primary and secondary outcomes in PTR and PR groups. Intention-to-treat principle

                        Within-group changes from baseline (95% CI)                                                    
  --------------------- --------------------------------------------- ----------------------- ------------------------ -----------------------
  Primary outcome                                                                                                      
   6MWD, min            17.2 (5.8 to 28.5)\*                          22.0 (5.0 to 39.1)\*    23.5 (12.1 to 35.0)\*    11.0 (−5.2 to 27.2)
  Secondary outcomes                                                                                                   
   30sec-STS, reps      1.3 (0.4 to 2.0)\*                            1.1 (0.1 to 2.0)\*      1.7 (0.9 to 2.5)\*       1.5 (0.5 to 2.3)\*
   CAT, points          −1.7 (−3.2 to −0.2)\*                         −0.5 (−1.9 to 1.1)      −0.3 (−1.8 to 1.2)       −1.0 (−2.5 to 0.6)
  HADS                                                                                                                 
   Anxiety, points      −1.0 (−1.7 to −0.2)\*                         −0.5 (−1.4 to 0.5)      0.1 (−0.6 to 0.8)        −0.3 (−1.2 to 0.7)
   Depression, points   −0.4 (−1.1 to 0.3)                            0.5 (−0.4 to 1.5)       0.3 (−0.4 to 1.0)        0.3 (−0.6 to 1.4)
   EQ5D-VAS, points     3.2 (−1.2 to 7.6)                             3.5 (−1.2 to 8.2)       2.9 (−1.4 to 7.2)        4.2 (−0.4 to 9.0)
  CCQ                                                                                                                  
   Function, points     −0.3 (−0.5 to −0.1)\*                         0.1 (−0.1 to 0.4)       −0.1 (−0.4 to 0.1)       0.1 (−0.2 to 0.5)
   Mental, points       −0.2 (−0.6 to 0.1)                            −0.1 (−0.5 to 0.3)      −0.1 (−0.4 to 0.2)       −0.1 (−0.4 to 0.3)
   Symptoms, points     −0.3 (−0.6 to −0.1)\*                         −0.2 (−0.5 to 0.1)      −0.2 (−0.4 to 0.1)       0.1 (−0.3 to 0.5)
   Total, points        −0.3 (−0.4 to −0.1)\*                         0.0 (−0.2 to 0.2)       −0.1 (−0.3 to 0.1)       0.1 (−0.2 to 0.3)
  PAL                                                                                                                  
   Steps per day        −116 (−503 to 270)                            −292 (−852 to 307)      −400 (−803 to −2.3)\*    −594 (−1164 to −57)\*
   Sedentary, min       29.0 (−29.9 to 95.4)                          18.8 (−11.8 to 49.3)    38.3 (−21.7 to 107.3)    10.1 (−21.0 to 41.3)
   Active, min          −29.0 (−95.4 to 29.9)                         −18.8 (−49.3 to 11.8)   −38.3 (−107.3 to 21.7)   −10.1 (−41.3 to 21.0)

Data are mean difference (95% CI). Estimates adjusted for baseline outcome measure. Estimates calculated for baseline measure equal to the mean baseline measure for study population.

\*P value within group changes \<0.05.

†Complete observations (n) used for the likelihood estimate from end of rehabilitation to baseline (PTR/PR): 6MWD: (56/59); 30-sec STS: (56/59); CAT: (59/62); HADS: (53/57); EQ5d-VAS: (57/62); CCQ: (57/62); PAL: (30/29).

‡Complete observations (n) used for the likelihood estimate from 22 weeks' follow-up from baseline to baseline (PTR/PR): 6MWD: (44/51); 30sec-STS: (44/51); CAT: (53/53); HADS: (50/50); EQ5d-VAS: (51/53); CCQ: (53/53); PAL: (28/27).

CAT, COPD Assessment Test; CCQ, COPD Clinical Questionnaire; EQ-5D, EuroQol 5-Dimension Questionnaire; HADS, Hospital Anxiety and Depression Scale; 6MWD, 6 min walk distance; PAL, physical activity level; PR, pulmonary rehabilitation; PTR, pulmonary tele-rehabilitation; 30sec-STS, 30 s sit-to-stand test; VAS, Visual Analogue Scale.

Results {#s3}
=======

Recruitment {#s3-1}
-----------

Of the patients suitable for hospital-based PR, 1099 met the inclusion criteria and were considered; 714 patients refused PR and were thus deemed ineligible. Of 385 eligible patients, the majority (n=251) wished to undertake conventional PR and declined participation in the study. One hundred and thirty-four patients provided informed consent and were randomised (n=67 in each group) ([figure 1](#F1){ref-type="fig"}). Baseline characteristics are shown in [table 1](#T1){ref-type="table"}.

![Consolidated Standards of Reporting Trials diagram. AMA, Amager; BBH, Bispebjerg; Disc, discogenic issue; FBH, Frederiksberg; FSH, Frederikssund; GEH, Gentofte; HEH, Herlev; HIL, Hillerød; HVH, Hvidovre; MI, myocardial infarction; OA, osteoarthritis; PR, pulmonary rehabilitation; PTR, pulmonary tele-rehabilitation, RCT, randomised controlled trial.](thoraxjnl-2019-214246f01){#F1}

Primary outcome {#s3-2}
---------------

[Tables 2 and 3](#T2 T3){ref-type="table"} show the differences between and the changes within the groups at the end of PR/PTR and at the 22 weeks' follow-up from baseline. We found no statistically significant between-group difference for change in the 6MWD after intervention ([table 2](#T2){ref-type="table"}). Both groups demonstrated statistically significant improvements in the 6MWD after intervention, but the gain was sustained and significant only in the PTR group at 22 weeks' follow-up from baseline ([table 3](#T3){ref-type="table"}). None of the group improvements exceeded the MCID at any measurement time point.

Secondary outcomes {#s3-3}
------------------

The between-group difference for changes in respiratory symptoms (CAT) was statistically different at the end of intervention with a greater symptom reduction difference of −1.6 points (p=0.04) in the PTR group that did not exceed the MCID ([table 2](#T2){ref-type="table"}). There was no between-group difference at the 22 weeks' follow-up from baseline. The groups did not exceed the MCID in respiratory symptom reduction at any measurement time point ([table 3](#T3){ref-type="table"}). The PTR group had a statistically significant reduction in anxiety and depression scores (HADS-A and HADS-D) compared with the conventional PR group after intervention, but it did not exceed the MCID. There were no between-group differences at the 22-week follow-up ([table 2](#T2){ref-type="table"}). The within group improvements on the anxiety domain were significant for the PTR group after intervention but did not exceed the MCID and the improvement was not sustained at the 22-week follow-up. No group exceeded the MCID for QoL (EQ-5D-VAS) and lower limb muscle function (30sec-STS) ([table 3](#T3){ref-type="table"}). We registered a statistically significant decrease in number of daily steps per day in the PR group from baseline to end of intervention and to the 22-week follow-up, whereas daily steps per day remained unchanged in the PTR group ([table 3](#T3){ref-type="table"}). There was no difference between groups in the per-protocol analyses in any outcome at any measurement time point (see [online supplementary tables S2 and S3](#SP1){ref-type="supplementary-material"}).

The attendance rate was a median of 25 session (IQR: 20 to 28) in the PTR group and 16 session (IQR: 8 to 19) in the PR group and thus the exercise volume was a median of 750 min (IQR: 600 to 840) in the PTR group and 960 min (IQR: 480 to 1140) in the PR group. A significantly higher number of patients remained in the PTR programme for the full intervention period compared with the PR programme (PTR: 57/67 vs PR: 43/67; OR: 3.18 (95% CI: 1.37 to 7.35), p\<0.01). However, there was no difference between groups for those who attended ≥70% of the programs' total sessions, (PTR: 49/67 vs PR: 42/67; OR: 1.68 (95% CI: 0.78 to 3.37), p\<0.27). The mean adherence rate among drop-outs who attended at least one session was 50% of all sessions (IQR%: 42 to 64) in the PTR programme versus 33% of all sessions (IQR%: 18 to 49) in the PR programme. Two drop-outs, both in the PR group, were potentially related to adverse effects of the PR programme. Both events were related to overload with subsequent pain in the knee and groin, respectively, and did not require medical treatment. In total, 41 hospital admissions related to COPD exacerbations were recorded (PTR: n=21; PR: n=20; p=0.77) during the rehabilitation period, and 74 hospitalisations related to COPD exacerbations (PTR: n=38; PR: n=36; p=0.97) were recorded at the 22-week follow-up (see the [online supplementary S](#SP1){ref-type="supplementary-material"} for diagnostic codes used in the registry from the National Health Data Authorities and [online supplementary S5](#SP1){ref-type="supplementary-material"} for hospital days and outpatient visits). There was no significant difference between groups for all cause hospitalisations during rehabilitation. Three deaths (PTR: n=1; PR: n=2) occurred during the rehabilitation period, and another three had died at the 22-week follow-up (p=1.0).

No difference could be shown between patients with and without missing outcome measurement on sex, all p values \>0.07. By contrast, the median age was significantly higher among patients with missing values for 6MWD, 30sec-STS, repetitions and CCQ mental score.

Registered problems with the technical solution {#s3-4}
-----------------------------------------------

Major technical issues leading to cancellation and rescheduling of group sessions affected 2 of 360 group sessions. Minor temporary technical issues (ie, sound artefacts, screen freezes) not leading to cancellation or delay were present in 14% of the total group session (49/360). Individual patient cancellation caused by technical problems was 12 of 1902 individual connections.

Discussion {#s4}
==========

The main finding of this multicentre, single-blinded, randomised clinical trial was that supervised PTR was not superior to conventional hospital-based PR regarding walking capacity (6MWD). More patients completed PTR than PR, whereas, contrary to our pre-hypothesis, there was no between-group difference in adherence rate (attending ≥70% of the planned sessions).

To our knowledge, the effects of a supervised PTR programme compared with a supervised conventional PR programme have not been previously investigated. Tsai *et al* found a clinically relevant effect on 6MWD and endurance shuttle walk test (ESWT) from supervised PTR compared with no intervention.[@R16] The study by Bernocchi *et al* [@R15] including patients with both COPD and heart failure reported superiority on 6MWD from an individual home-monitored exercise programme with a weekly phone call compared with no intervention; the intervention group exceeded the MCID and maintained the gain at the 2-month follow-up.[@R15] The studies by Bourne *et al* [@R13] and Chaplin *et al* [@R14] compared the effect of unsupervised web-based or video-demonstrated individual exercise and education with conventional group PR and found comparable between-group effects on walking tests and within-group changes that exceeded the MCID for 6MWD and ESWT but not for incremental shuttle walk test.[@R13]

By contrast, we found that neither conventional PR nor PTR improved the 6MWD above the MCID. Differences in population characteristics could in part explain our negative result. Compared with the above-mentioned studies, patients in our cohort had lower FEV~1~, higher symptom burden, more exacerbations, lower walking capacity and most likely more locomotor disadvantages because in our study, 34% used a walking aid. Use of a walking aid or other indications of frailty have not been reported in the previous PTR studies.[@R13] We recruited patients with identical real-world inclusion criteria for hospital-based PR, which could limit the consistency and efficacy of the results; however, our study reflects routine practice. Recently, two large RCTs by Holland *et al* [@R27] and Horton *et al* [@R28] including in total 453 patients with COPD, compared home-based PR with supervised centre-based PR, using a pragmatic trial design, also failed to achieve the expected MCID on walking capacity from both interventions. Finally, a retrospective cohort study of 2068 patients with COPD of differing severity and with different characteristics receiving gold standard outpatient or inpatient PR in the Netherlands reported that only 40% to 50% of all patients exceeded the MCID for 6MWD, HADS-A, HADS-D and St George\'s Respiratory Questionnaire, while the group average improvement almost exceeded the MCID.[@R29] In this study, Spruit and colleagues demonstrated that patients respond very heterogeneously on both the physical and self-reported clinical outcomes. This suggests the need for reconsideration of the assumption that all patients with COPD are likely to respond similarly and sufficiently to specific and restricted primary outcomes in either conventional PR programs[@R29] or alternative home-based programs.[@R27]

From the Cochrane review it appears that 43% of the larger studies (including more than 30 participants in each group) did not exceed the MCID for the 6MWD[@R1] and, importantly, meta-epidemiological studies have shown that single-centre trials yield 14% to 27% larger effect sizes than do multicentre trials even when analyses are adjusted for sample size and bias.[@R30]

The completion rate in our study was significantly higher in the PTR group than in the PR group; however, we did not find a significant higher adherence rate in the PTR group (73%) compared with the PR group (62%). The drop-out rate of 36% in the PR group was anticipated and comparable to other studies reporting drop-out rates from 10% to 50%.[@R6] The annual 2018 data audit from the Danish Regional Quality Database in COPD revealed that 45% of all participants in Danish outpatient hospital PR adhere to less than 50% of the PR program.[@R32] The real-world data from this quality database reflect the challenges with adherence in a conventional hospital-based real-world PR programme and should be contrasted with the distinctly higher adherence in the PTR programme, where 73% of patients attended ≥70% of the sessions. Thus, PTR seemingly has the potential to overcome some barriers to adherence and completion. It should be noted that only one-third of patients eligible for this study were willing to participate in this RCT as they stated 'preferring conventional PR', thus limiting the external validity ([figure 1](#F1){ref-type="fig"}). Patient preferences and motivation have a potential impact on the outcomes achieved in different settings. This indicates that PTR could be an alternative for some patients eligible for outpatient hospital-based PR. As the 134 patients who agreed to participate may be particularly motivated, the 608 patients who declined participation in conventional PR would be an important group of interest for future research in the field of exploring the relevance and effects of PTR as an alternative delivery model.

There were also a number of important secondary findings in the present study. We investigated a cohort of patients with an extremely low level of physical activity, with average steps per day corresponding to basal and limited activity, for example, getting out of bed, making a meal and infrequent walks outside the home. This low and unchanged PAL throughout the study could affect the outcome and explain why the MCID in 6MWD was not exceeded since PAL and steps above 7500 per day are considered essential for physical functioning and overall health.[@R33]

We found that the PTR group had a significant reduction in CAT, anxiety and depression scores (HADS-A and HADS-D) compared with the PR group after intervention; however, the reduction did not exceed the MCID and the difference was not persistent at the 22-week follow-up. The higher completion rate in the PTR group, where patients continued to receive real-time attention and care, could be a plausible explanation of the differences after intervention. The previously mentioned PTR studies by Chaplin *et al* [@R14] and Bourne *et al* [@R13] did not find any between-group differences in HADS after intervention, while Tsai *et al* [@R16] found differences identical to ours with supervised PTR compared with no intervention. The impact of real-time supervision versus the web-based PTR, including the means of communication, is not possible to quantify but could potentially explain some of these inconsistent findings between the PTR studies.

We are not aware of any studies comparing non-supervised PTR with supervised PTR. Ability to navigate and interact independently on a tablet and a webpage was required in the non-supervised PTR studies, whereas for the patients in our study, it was sufficient to have naive technical ability and skills.[@R13] Essentially, future tele-rehabilitation designs must include specific considerations regarding delivery form and content and technical skills of the targeted population, particularly if PTR is to be considered as an extended offer specifically to those who live remotely and to those who lack energy and resources to join a conventional PR programme.

The strengths of this study include the multicentre design, rigorous methodology, powering for an adequate sample size to test our *a priori* hypothesis and the intention-to-treat analysis, which limits the risk of bias. We recruited patients with severely progressed COPD using national inclusion and exclusion criteria identical to routine clinical practice for conventional outpatient hospital-based PR. Blinding was also a strength of the present study. Our assessment of outcomes was performed with documented small and acceptable measurement errors.[@R21] A limitation of the study concerns the small but real variation in exercise content and volume among the seven hospitals delivering conventional PR, which was not possible to monitor and align. However, this is a true reflection of the real-world setting and thereby a real-world comparison. Different practical challenges to modelling, staffing and structuring PTR and differing patient acceptance of PTR in different countries, geographical regions and different types of healthcare system are limitations of the generalisability of our findings.

Proper organisation of PTR remains a challenge. It is a delicate balance in terms of decision-makers not limiting access to outpatient conventional PR and replacing it with PTR to save the costs related to buildings, equipment, transportation, etc, while endeavouring to provide an option for patients who are unable to attend the outpatient programme. From our perspective, many research questions remain unanswered regarding PTR. Future research should address subjects such as which patients are best suited to PTR and how we accommodate the increasing focus on personalised training. We need to find ways to enhance digital literacy among elderly, frail patients and discover whether the supervised or web-based tele-model is more effective as well as cost-effective. Furthermore, it is not yet known if applications will be as as good as online groups with videoconferencing. Other aspects include the role of monitoring PTR and the long-term health-related and QoL-related outcomes. Another issue regarding future studies of both PR and PTR concerns the measured outcomes of interest. As results to date regarding the traditional exercise and QoL outcomes are not convincing in patients with severe disease status, it is necessary to try a different approach. Outcomes that embrace activities of daily living and/or reduce symptoms such as dyspnoea and fatigue are warranted. In the study by Spruit *et al* [@R29] a composite endpoint for response to a 40-session PR programme was constructed and patients were clustered according to response profile. Interestingly, those in the 'very good responder' cluster were characterised by a worse baseline health status in comparison with the other clusters. However, it was unclear whether this multidimensional response was driven by a single outcome measure or several measures, thus calling for further research in the context of composite outcomes.

Conclusion {#s5}
==========

In conclusion, supervised PTR was not superior to supervised conventional PR in increasing 6MWD. Improvements in completion of PTR compared with PR were found; however, future non-inferiority studies of the 6MWD for PTR and PR are needed to justify recommending PTR based on better adherence to the programme.
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